BRPI0709340A2 - mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma - Google Patents

mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma Download PDF

Info

Publication number
BRPI0709340A2
BRPI0709340A2 BRPI0709340-3A BRPI0709340A BRPI0709340A2 BR PI0709340 A2 BRPI0709340 A2 BR PI0709340A2 BR PI0709340 A BRPI0709340 A BR PI0709340A BR PI0709340 A2 BRPI0709340 A2 BR PI0709340A2
Authority
BR
Brazil
Prior art keywords
ras
protein
amino acid
nucleic acid
wild
Prior art date
Application number
BRPI0709340-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Guo Zhimin
Lu Yingnian
Franzusoof Alex
Bellgrau Donald
Original Assignee
Globeimmune, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune, Inc. filed Critical Globeimmune, Inc.
Publication of BRPI0709340A2 publication Critical patent/BRPI0709340A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
BRPI0709340-3A 2006-03-27 2007-03-09 mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma BRPI0709340A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78656806P 2006-03-27 2006-03-27
US60/786,568 2006-03-27
PCT/US2007/063711 WO2007133835A2 (en) 2006-03-27 2007-03-09 Ras mutation and compositions and mehods related thereto

Publications (1)

Publication Number Publication Date
BRPI0709340A2 true BRPI0709340A2 (pt) 2013-04-16

Family

ID=38694572

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0709340-3A BRPI0709340A2 (pt) 2006-03-27 2007-03-09 mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma

Country Status (12)

Country Link
US (3) US7745128B2 (enExample)
EP (1) EP2004666B1 (enExample)
JP (2) JP2009531068A (enExample)
KR (1) KR20090008290A (enExample)
CN (1) CN101448848B (enExample)
AU (1) AU2007249639B2 (enExample)
BR (1) BRPI0709340A2 (enExample)
CA (1) CA2647102A1 (enExample)
MX (1) MX2008012392A (enExample)
SG (1) SG170763A1 (enExample)
TW (1) TW200806789A (enExample)
WO (1) WO2007133835A2 (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
JP4914990B2 (ja) 2002-12-16 2012-04-11 グローブイミューン，インコーポレイテッド 動物を癌から守るための治療用組成物
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
WO2007008780A2 (en) * 2005-07-11 2007-01-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
TW200806789A (en) * 2006-03-27 2008-02-01 Globeimmune Inc RAS mutation and compositions and methods related thereto
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN101687030B (zh) * 2007-02-02 2014-07-02 环球免疫公司 用于生产基于酵母的疫苗的方法
WO2008115610A1 (en) * 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
ES2685636T3 (es) * 2007-06-29 2018-10-10 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Método de fijación y expresión de sustancia fisiológicamente activa
KR100957555B1 (ko) 2007-12-28 2010-05-11 덕성여자대학교 산학협력단 Ｒａｓ 융합 단백질
US20110081362A1 (en) * 2008-01-31 2011-04-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
US20100075326A1 (en) * 2008-09-12 2010-03-25 Cornell University Yeast surface two-hybrid system for quantitative detection of protein-protein interactions
KR101153845B1 (ko) 2008-11-10 2012-07-09 단국대학교 산학협력단 Ｋｒａｓ Ｇ１２Ｖ ＲＮＡ를 특이적으로 인지할 수 있는 트랜스-스플라이싱 그룹 Ｉ 리보자임
EP2350320A4 (en) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
JP6010458B2 (ja) * 2009-04-03 2016-10-19 ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 非対称二本鎖ｒｎａによる特異的阻害のための、方法および組成物
ES2660597T3 (es) 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
WO2011087928A1 (en) * 2010-01-12 2011-07-21 Siemens Healthcare Diagnostics Inc. Oligonucleotides and methods for detecting kras and pik3ca mutations
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
MX342055B (es) * 2010-04-12 2016-09-12 Response Genetics Inc Iniciadores y sondas de kras.
AU2011305445B2 (en) 2010-09-24 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
PE20140844A1 (es) 2011-02-12 2014-07-14 Globeimmune Inc Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
US9556473B2 (en) 2011-02-15 2017-01-31 Leica Biosystems Newcastle Ltd Methods for identifying nucleic acid sequences
JP5881746B2 (ja) 2011-02-15 2016-03-09 ライカ バイオシステムズ ニューキャッスル リミテッド ｍＲＮＡの局在インサイチュー検出のための方法
JP6068368B2 (ja) 2011-03-17 2017-01-25 グローブイミューン，インコーポレイテッド 酵母−ブラキュリ免疫治療組成物
CN107320734A (zh) 2011-04-29 2017-11-07 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
CN102796811B (zh) * 2011-05-26 2013-12-18 上海赛安生物医药科技有限公司 检测kras突变的试剂及方法
EP2720716B1 (en) 2011-06-14 2018-03-21 Globeimmune, Inc. Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection
CN109010809A (zh) 2011-08-17 2018-12-18 全球免疫股份有限公司 酵母-muc1免疫治疗组合物及其用途
EP2776586B1 (en) * 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
US9260714B2 (en) * 2011-12-02 2016-02-16 Roche Molecular Systems, Inc. Suppression of non-specific amplification with high-homology oligonucleotides
KR101153844B1 (ko) 2012-04-17 2012-06-20 단국대학교 산학협력단 Ｋｒａｓ Ｇ１２Ｖ ＲＮＡ를 특이적으로 인지할 수 있는 트랜스-스플라이싱 그룹 Ｉ 리보자임
EP2854779A1 (en) * 2012-05-31 2015-04-08 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
KR102103319B1 (ko) * 2012-06-26 2020-04-22 바이오디식스, 인크. 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법
AU2013359469B2 (en) * 2012-12-10 2019-05-16 Seattle Biomedical Research Institute Cell-free biofragment compositions and related systems, devices, and methods
MX374829B (es) 2013-03-19 2025-03-06 Globeimmune Inc Composición a base de levadura para usarse para tratar cordoma.
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
CN105307641A (zh) 2013-05-03 2016-02-03 西莱克塔生物科技公司 用于降低不期望体液免疫应答的给药组合
TWI654200B (zh) 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
WO2015059677A1 (en) 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
BR112016013138A2 (pt) * 2013-12-09 2018-01-16 Targovax Asa mistura de peptídeos
WO2015123532A1 (en) * 2014-02-16 2015-08-20 Globeimmune, Inc. Ras g12r immunotherapy for ras mutation-positive cancers
CA2948803A1 (en) * 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
CA2946759A1 (en) 2014-04-25 2015-10-29 Memorial Sloan-Kettering Cancer Center Treatment of h-ras-driven tumors
KR101602876B1 (ko) * 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
US10829752B2 (en) * 2014-08-01 2020-11-10 Northwestern University Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders
US12415995B2 (en) 2014-08-01 2025-09-16 Northwestern University Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders
EP3180463B1 (en) * 2014-08-15 2023-08-30 Medimmune, LLC Detecting residual host cell proteins in recombinant protein preparations
EA201790551A1 (ru) 2014-09-07 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору
JP2018518177A (ja) * 2015-06-16 2018-07-12 タルゴバックス エーエスエー Ｒａｓタンパク質の突然変異フラグメント
TWI748957B (zh) 2015-08-03 2021-12-11 美商環球免疫公司 經修飾之酵母-短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物
US10612032B2 (en) * 2016-03-24 2020-04-07 The Board Of Trustees Of The Leland Stanford Junior University Inducible production-phase promoters for coordinated heterologous expression in yeast
JP2019520086A (ja) 2016-05-27 2019-07-18 オラム・セラピューティクス・インコーポレイテッド 細胞質浸透抗体およびその用途
CN118064425A (zh) 2016-11-16 2024-05-24 斯坦福大学托管董事会 用于鉴定和表达基因簇的系统和方法
MX2019009070A (es) * 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
WO2018145020A1 (en) * 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
EP4599848A3 (en) 2017-03-11 2025-12-03 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
JP7722629B2 (ja) * 2017-07-04 2025-08-13 キュアバック エスイー 新規核酸分子
CN108250269A (zh) * 2018-04-02 2018-07-06 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440647A (zh) * 2018-04-02 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440648A (zh) * 2018-04-02 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108484731A (zh) * 2018-04-02 2018-09-04 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440646A (zh) * 2018-04-02 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108484730A (zh) * 2018-04-02 2018-09-04 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN119818663A (zh) 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
KR20190143826A (ko) 2018-06-21 2019-12-31 오름테라퓨틱 주식회사 세포/조직 특이적 세포 침투 항체
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CA3170359A1 (en) 2020-04-14 2021-10-21 Nantcell, Inc. Yeast lysate covid-19 vaccine
IL300026A (en) * 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2377188A (en) * 1941-08-07 1945-05-29 Schering Corp Stabilized filter preparations
US2376884A (en) * 1941-08-07 1945-05-29 Schering Corp Hydroquinone composition
US3856934A (en) * 1970-06-24 1974-12-24 A Kligman Skin depigmentation
US3755560A (en) * 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
US4136166A (en) * 1977-04-18 1979-01-23 Helena Rubinstein, Inc. Skin lightening composition
US4229427A (en) * 1978-06-28 1980-10-21 The Procter & Gamble Company Radioactive scanning agents with hydroquinone stabilizer
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
JPS57145803A (en) * 1981-03-05 1982-09-09 Sunstar Inc External decoloring agent for skin
US4421769A (en) * 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US4466955A (en) * 1982-06-09 1984-08-21 Germaine Monteil Cosmetiques Corporation Skin bleaching stick containing hydroquinone
US4725550A (en) 1984-01-19 1988-02-16 Research Foundation Of State University Of New York Novel mutation of the c-K-ras oncogene activated in a human lung carcinoma
US5591582A (en) 1985-07-23 1997-01-07 The Board Of Rijks Universiteit Leiden Methods for detecting activated RAS oncogenes
US4871838A (en) 1985-07-23 1989-10-03 The Board Of Rijks Universiteit Leiden Probes and methods for detecting activated ras oncogenes
US4792443A (en) * 1985-12-20 1988-12-20 Warner-Lambert Company Skin bleaching preparations
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
JPH0474515A (ja) * 1990-07-13 1992-03-09 Toray Ind Inc 酸素吸収体
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US5523077A (en) * 1992-02-06 1996-06-04 Yale University Composition and method for whitening skin
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
JPH09500650A (ja) * 1993-07-26 1997-01-21 ケイ．オー．テクノロジー インコーポレイテッド ガン治療薬の主薬としての遺伝子の異なる対立遺伝子の阻害剤
GB9422814D0 (en) 1994-11-11 1995-01-04 Medinnova Sf Chemical method
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US6497860B1 (en) * 1996-11-04 2002-12-24 Children's Hospital Medical Center Skin lightening compositions
US6060297A (en) * 1997-04-17 2000-05-09 Incyte Pharmaceuticals, Inc. Rho protein
US5945306A (en) * 1997-12-16 1999-08-31 Incyte Pharmaceuticals, Inc. Ras protein
US6207450B1 (en) * 1998-04-15 2001-03-27 University Of Iowa Research Foundation Glaucoma therapeutics and diagnostics based on a novel human transcription factor
US6017710A (en) * 1998-05-13 2000-01-25 Axys Pharmaceuticals, Inc. RAQ genes and their uses
NO309798B1 (no) 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
CA2385134A1 (en) * 1999-10-15 2001-04-19 Wakenyaku Co., Ltd. Template molecule having broad applicability and highly efficient function means of cell-free synthesis of proteins by using the same
AUPQ495700A0 (en) * 2000-01-05 2000-02-03 Johnson & Johnson Research Pty. Limited Method for concurrent amplification and real time detection of polymorphic nucleic acid sequences
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
JP2004508056A (ja) * 2000-09-06 2004-03-18 グラクソ　グループ　リミテッド ５−ヒドロキシトリプタミン受容体遺伝子多型、および治療に対する応答
AU2002225681A1 (en) 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US7189759B2 (en) * 2001-05-23 2007-03-13 Medicis Pharmaceutical Corporation Compositions for the treatment of pigmentation disorders and methods for their manufacture
US6699464B1 (en) * 2001-07-30 2004-03-02 Stiefel Laboratories, Inc. Compositions for treatment of hyperpigmentation and methods for making and using such compositions
GB0130955D0 (en) * 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
US20040185016A1 (en) * 2002-07-30 2004-09-23 Popp Karl F Compositions for treatment of hyperpigmentation and methods for making and using such compositions
GB0229139D0 (en) * 2002-12-13 2003-01-15 Glaxo Group Ltd Gene polymorphisms
JP4914990B2 (ja) * 2002-12-16 2012-04-11 グローブイミューン，インコーポレイテッド 動物を癌から守るための治療用組成物
WO2007008780A2 (en) 2005-07-11 2007-01-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
TW200806789A (en) * 2006-03-27 2008-02-01 Globeimmune Inc RAS mutation and compositions and methods related thereto
CN101687030B (zh) 2007-02-02 2014-07-02 环球免疫公司 用于生产基于酵母的疫苗的方法
WO2008115610A1 (en) 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer

Also Published As

Publication number Publication date
US20070224208A1 (en) 2007-09-27
MX2008012392A (es) 2008-12-17
CN101448848B (zh) 2013-12-04
CA2647102A1 (en) 2007-11-22
WO2007133835A2 (en) 2007-11-22
SG170763A1 (en) 2011-05-30
WO2007133835A8 (en) 2010-11-11
CN101448848A (zh) 2009-06-03
JP2009531068A (ja) 2009-09-03
AU2007249639A1 (en) 2007-11-22
US8470313B2 (en) 2013-06-25
JP2015043773A (ja) 2015-03-12
EP2004666A4 (en) 2009-11-18
TW200806789A (en) 2008-02-01
KR20090008290A (ko) 2009-01-21
US20100215678A1 (en) 2010-08-26
EP2004666B1 (en) 2014-09-03
US20130344097A1 (en) 2013-12-26
AU2007249639B2 (en) 2012-05-31
EP2004666A2 (en) 2008-12-24
WO2007133835A3 (en) 2008-11-13
US7745128B2 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
AU2007249639B2 (en) Ras mutation and compositions and methods related thereto
AU2008229295B2 (en) Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
JP5809067B2 (ja) 癌の診断および治療のための方法および組成物
ES2883335T3 (es) Métodos y composiciones para el diagnóstico y tratamiento del glioblastoma
JP4822490B2 (ja) 腫瘍形成形質転換に関連する内因性レトロウイルスポリペプチド
JP2020062014A (ja) ポリペプチド、核酸およびその使用
JP2008285485A (ja) 悪性新生物の診断および処置
JP2007534748A (ja) 腫瘍抑制因子として作用するａｉｍ３の新規用途
BRPI1008564B1 (pt) Método para detecção, diagnóstico ou monitoramento de uma doença tumoral
KR20020073181A (ko) Ｌｉｖ-1 관련 단백질, 이를 코딩하는 폴리뉴클레오티드및 암의 치료를 위한 그의 용도
ES2453374T3 (es) Método para determinar si una célula tumoral presenta potencial invasivo y/o metastásico, y agentes moduladores de la transformación maligna
JP2011530283A (ja) がんの診断および治療のためのｖｈｚ
CN101437399A (zh) 调节免疫应答的方法和试剂
CN114058699B (zh) Ppdpf在胰腺癌诊断及药物制备中的应用
CN110244056B (zh) Znf521基因在制备肝癌治疗药物、诊断及预后评估试剂中的应用
EP2699599B1 (en) Gpr177 as target and marker in tumors
US20090202552A1 (en) Gene expressed in prostate cancer and methods of use
CN105624275B (zh) Eif4g1在鳞癌诊断和治疗中的应用
CN113398270B (zh) 一种治疗骨巨细胞瘤的方法
EP1344064A2 (en) Compositions and methods relating to prostate specific genes and proteins
CN121041442A (zh) 膜型glyr1分子作为胰腺癌治疗靶点的应用
US20100113557A1 (en) Method for prevention of tumor
HK1232453B (en) Novel cancer antigen eef2
WO2002036623A2 (en) Ghep, a gene highly expressed in normal and neoplastic prostate, and uses therefor
HK1189514B (en) Eef2-derived peptides for the treatment or prevention of cancer

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: INTERESSADO: O DEPOSITANTE DESPACHO: APRESENTE O DEPOSITANTE A TRADUCAO DO RELATORIO DA LISTAGEM DE SEQUENCIA CONFORME DETERMINA O ATO NORMATIVO NO 128 DE 05/03/1997, ITENS 9.2 E 9.2.1.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2368 DE 24-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.